{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=darunavir%2Fritonavir&page=4", "query": { "intervention": "darunavir/ritonavir", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 74, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=darunavir%2Fritonavir&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=darunavir%2Fritonavir&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T00:45:08.509Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00665847", "title": "TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "Etravirine (TMC125)", "type": "DRUG" }, { "name": "Optimized background regimen (OBR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 103, "start_date": "2008-11", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2015-04-23", "last_synced_at": "2026-10-04T00:45:08.509Z", "location_count": 13, "location_summary": "Mobile, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00665847" }, { "nct_id": "NCT01869634", "title": "Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Human Immunodeficiency Virus Infection" ], "interventions": [ { "name": "darunavir with ritonavir and fixed-dose viread+emtricitabine daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 37, "start_date": "2013-06", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-10-04T00:45:08.509Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01869634" }, { "nct_id": "NCT00827112", "title": "A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus-1" ], "interventions": [ { "name": "maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 129, "start_date": "2009-03", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-06-15", "last_synced_at": "2026-10-04T00:45:08.509Z", "location_count": 27, "location_summary": "Los Angeles, California • Norwalk, Connecticut • Washington D.C., District of Columbia + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00827112" }, { "nct_id": "NCT01400412", "title": "Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Emtricitabine", "type": "DRUG" }, { "name": "Placebo for Tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Placebo for Maraviroc", "type": "DRUG" }, { "name": "Maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 262, "start_date": "2012-01-17", "completion_date": "2014-06-30", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-10-04T00:45:08.509Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01400412" }, { "nct_id": "NCT00517192", "title": "Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Tipranavir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2007-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-05-14", "last_synced_at": "2026-10-04T00:45:08.509Z", "location_count": 9, "location_summary": "Beverly Hills, California • Fort Lauderdale, Florida • Miami, Florida + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00517192" }, { "nct_id": "NCT04518228", "title": "Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV", "Tuberculosis" ], "interventions": [ { "name": "Bictegravir (BIC)", "type": "DRUG" }, { "name": "Tenofovir alafenamide (TAF)", "type": "DRUG" }, { "name": "Long-acting injectable formulation of cabotegravir (CAB LA)", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Atazanavir/ritonavir (ATV/r)", "type": "DRUG" }, { "name": "Darunavir/ritonavir (DRV/r)", "type": "DRUG" }, { "name": "Lopinavir/ritonavir (LPV/r)", "type": "DRUG" }, { "name": "Cobicistat", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "First-Line TB Treatment", "type": "DRUG" }, { "name": "Second-Line TB Treatment", "type": "DRUG" }, { "name": "Doravirine (DOR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 205, "start_date": "2021-09-01", "completion_date": "2025-07-10", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-04T00:45:08.509Z", "location_count": 13, "location_summary": "Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518228" }, { "nct_id": "NCT01605084", "title": "Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Optimized NRTI backbone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2012-06-30", "completion_date": "2014-08-31", "has_results": false, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-10-04T00:45:08.509Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01605084" }, { "nct_id": "NCT01423812", "title": "DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Twice-daily combination Darunavir and ritonavir", "type": "DRUG" }, { "name": "Once-daily combination Darunavir and ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ruth M. Rothstein CORE Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2012-01", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-10-04T00:45:08.509Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01423812" }, { "nct_id": "NCT00993148", "title": "Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection", "HIV Infections" ], "interventions": [ { "name": "maraviroc", "type": "DRUG" }, { "name": "darunavir", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2010-05", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-09-05", "last_synced_at": "2026-10-04T00:45:08.509Z", "location_count": 5, "location_summary": "San Francisco, California • Miami, Florida • Chicago, Illinois + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00993148" }, { "nct_id": "NCT00258557", "title": "TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir (\"TMC114/r\") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "LPV/RTV", "type": "DRUG" }, { "name": "TMC-114/RTV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 692, "start_date": "2005-09", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-04T00:45:08.509Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00258557" } ] }